PVCT Stock Overview
A clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Provectus Biopharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.12 |
| 52 Week High | US$0.22 |
| 52 Week Low | US$0.044 |
| Beta | 0.58 |
| 11 Month Change | 11.12% |
| 3 Month Change | 0.33% |
| 1 Year Change | -11.19% |
| 33 Year Change | 118.80% |
| 5 Year Change | 77.63% |
| Change since IPO | -89.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| PVCT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 8.9% | 1.6% | 2.2% |
| 1Y | -11.2% | 10.0% | 31.7% |
Return vs Industry: PVCT underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: PVCT underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| PVCT volatility | |
|---|---|
| PVCT Average Weekly Movement | 10.4% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PVCT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PVCT's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 4 | Ed Pershing | www.provectusbio.com |
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company’s lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.
Provectus Biopharmaceuticals, Inc. Fundamentals Summary
| PVCT fundamental statistics | |
|---|---|
| Market cap | US$47.79m |
| Earnings (TTM) | -US$3.03m |
| Revenue (TTM) | US$723.92k |
69.6x
P/S Ratio-16.6x
P/E RatioIs PVCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PVCT income statement (TTM) | |
|---|---|
| Revenue | US$723.92k |
| Cost of Revenue | US$1.81m |
| Gross Profit | -US$1.09m |
| Other Expenses | US$1.94m |
| Earnings | -US$3.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0072 |
| Gross Margin | -150.69% |
| Net Profit Margin | -418.37% |
| Debt/Equity Ratio | -51.0% |
How did PVCT perform over the long term?
See historical performance and comparison